In the latest close session, Boston Scientific (BSX) was down 1.2% at $44.60. The stock trailed the S&P 500, which registered a daily gain of 0.72%. On the other hand, the Dow registered a gain of 0.3%, and the technology-centric Nasdaq increased by 1.12%.
The medical device manufacturer's stock has dropped by 7.02% in the past month, falling short of the Medical sector's gain of 12.48% and the S&P 500's loss of 0.9%.
The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. The company is scheduled to release its earnings on July 29, 2026. The company is forecasted to report an EPS of $0.83, showcasing a 10.67% upward movement from the corresponding quarter of the prior year. At the same time, our most recent consensus estimate is projecting a revenue of $5.39 billion, reflecting a 6.54% rise from the equivalent quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
Any recent changes to analyst estimates for Boston Scientific should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.32% lower within the past month. Right now, Boston Scientific possesses a Zacks Rank of #4 (Sell).
In terms of valuation, Boston Scientific is currently trading at a Forward P/E ratio of 13.44. Its industry sports an average Forward P/E of 19.08, so one might conclude that Boston Scientific is trading at a discount comparatively.
We can additionally observe that BSX currently boasts a PEG ratio of 0.86. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Products industry currently had an average PEG ratio of 1.73 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 170, positioning it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).